Mounjaro®
Starting from £179.99/mo
Start journey Learn moreRapid weight loss on any treatment carries a real risk of losing lean muscle alongside fat — and Wegovy is no exception. Clinical data from the STEP 1 trial, published in the New England Journal of Medicine, show that meaningful proportions of weight lost during semaglutide treatment can come from lean mass, not just adipose tissue. That makes protecting muscle an active priority, not a passive bonus. These are prescription-only medicines, and a GPhC-registered prescriber will assess what's clinically appropriate for you specifically — but the strategies below are grounded in the evidence and in practical guidance your clinical team will want you to follow.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP trials reported impressive average weight reductions, roughly 15% of body weight over 68 weeks at the 2.4mg maintenance dose. What the headline figures don't always surface is the composition of that loss. In weight-loss studies broadly, and in GLP-1 trials specifically, somewhere between 25% and 40% of total weight lost can come from lean tissue rather than fat, depending on how active participants are and how much protein they eat. The STEP 1 data, reviewed by the NHS in its semaglutide patient guidance, note that combining treatment with dietary and activity changes is part of the licensed recommendation, this isn't boilerplate; it directly affects what you preserve.
Wegovy's appetite-suppressing effect is powerful. That's the point. But it applies indiscriminately to protein-rich meals as much as to high-calorie snacks. People on treatment often find they can comfortably eat far less without feeling hungry, which sounds ideal until the protein deficit quietly erodes muscle over weeks. Knowing this upfront is half the battle.
Cardio burns calories. Resistance training (weights, bands, bodyweight exercises, reformer Pilates) sends a hormonal signal to your body to retain and rebuild muscle fibres. During a caloric deficit, that signal becomes critical. Without it, your body has little reason to maintain metabolically expensive muscle tissue.
You don't need to be in a gym five days a week. Two to three sessions of meaningful resistance work per week, covering major muscle groups (legs, back, chest, arms), consistently maintained across your treatment period, is what the evidence supports. If you're new to strength training, starting with bodyweight squats, press-ups and rows is entirely sufficient. Keep your gym bag packed and ready, the sessions you don't have to think about are the ones that happen. Progress gradually, and let your prescriber know if fatigue or GI symptoms are affecting your ability to train; timing your exercise relative to injection day can sometimes help.
There is a useful companion question about whether Wegovy causes muscle loss and what the evidence really shows, which is worth reading alongside this page.
A general starting point used in clinical weight-management contexts is roughly 1.2 to 1.6 grams of protein per kilogram of target or current body weight per day during active weight loss, though your prescriber or a registered dietitian will give you a figure suited to your situation. For most adults that means somewhere between 100g and 140g of protein daily. On Wegovy, achieving that when you can barely face a full meal requires deliberate planning rather than relying on hunger cues.
Practical approaches that patients find useful: prioritise protein in the first half of any meal, when appetite is strongest; choose protein-dense foods (eggs, Greek yoghurt, chicken, fish, legumes, cottage cheese) rather than trying to supplement your way to the target; and spread intake across the day rather than front-loading one large meal. Protein shakes are a legitimate tool if solid food feels difficult at higher doses, not a shortcut, just a practical bridge.
Staying well hydrated helps too. GI side effects from semaglutide (nausea, early fullness) are most pronounced in the early weeks and after dose increases, which is precisely when eating enough protein feels hardest. Work through that window, and it usually eases.
Muscle loss during weight loss also links to two things patients worry about later: loose skin and weight regain after stopping. Maintaining lean mass supports skin elasticity to a degree, which is why the question of preventing loose skin on Wegovy and the muscle question are related. Some patients are also concerned about facial changes during treatment, and our guide on how to prevent Wegovy face covers practical steps you can take to protect your appearance as you lose weight. Separately, muscle tissue is metabolically active, it burns more energy at rest than fat does. People who preserve it during treatment tend to find maintaining their new weight more manageable, which connects directly to the challenge of managing weight after stopping Wegovy.
The wider evidence on Wegovy's results, including the body-composition data, is covered in detail on our Wegovy weight-loss data page. And if you're weighing up how semaglutide compares to other treatment options, our overview of weight-loss treatments is a sensible next step. Understanding the cost context is also reasonable at this stage, the Wegovy cost page explains what to expect from private treatment pricing in the UK.
None of this replaces a clinical conversation. A prescriber who knows your starting point, your activity level, and your dietary habits can give you specific, personal guidance, and at nume, that review happens the same day you submit your consultation, by a real clinician. If you'd like that conversation, start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.